公开(公告)号：US12128108B2

公开(公告)日：2024-10-29

申请号：US17979450

申请日：2022-11-02

Applicant: Aihol Corporation

Inventor： Szu-Yuan Lee ,  Ping-Shan Lai ,  Chih-An Lin

IPC: A61K47/61 ,  A61K31/565 ,  A61K31/566 ,  A61K31/568 ,  A61K31/573 ,  A61K47/54 ,  A61P25/28

CPC classification number: A61K47/61 ,  A61K31/565 ,  A61K31/566 ,  A61K31/568 ,  A61K31/573 ,  A61K47/542 ,  A61P25/28

Abstract: Disclosed herein is a method of using a hyaluronan conjugate, which includes a hyaluronic acid (HA), a sex hormone, and a linker for coupling one of the disaccharide units of the HA and the sex hormone. The hyaluronan conjugates are used in treating neurodegenerative diseases.

公开(公告)号：US12121526B2

公开(公告)日：2024-10-22

申请号：US17128955

申请日：2020-12-21

Applicant: University of Maryland, Baltimore ,  The United States of America as Represented by the Department of Veterans Affairs

Inventor： J. Marc Simard

IPC: A61K31/64 ,  A61K31/57 ,  A61P9/10 ,  G01N33/68 ,  A61K31/427 ,  A61K31/565 ,  A61K38/00

CPC classification number: A61K31/57 ,  A61K31/64 ,  A61P9/10 ,  G01N33/6872 ,  A61K31/427 ,  A61K31/565 ,  A61K38/00

Abstract: The present invention concerns protection of an organ or tissue outside of the central nervous system following an ischemic episode. In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth. In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1. Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example.

公开(公告)号：US20240315959A1

公开(公告)日：2024-09-26

申请号：US18605521

申请日：2024-03-14

Applicant: Chemo Research, S.L.

Inventor： Enrico COLLI ,  Carlos DÍEZ FUERTES

IPC: A61K9/00 ,  A61K31/565 ,  A61K31/57 ,  A61K47/32 ,  A61K47/34

CPC classification number: A61K9/0039 ,  A61K31/565 ,  A61K31/57 ,  A61K47/32 ,  A61K47/34

Abstract: The present invention relates to a method for providing contraception in a female subject, comprising continuous intravaginal administration of levonorgestrel of from about 60 μg/day to about 100 μg/day. The invention further relates to a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea comprising continuously administering about 60 μg/day to about 160 μg/day of levonorgestrel. Delivery devices, such as, intravaginal rings for putting the methods in practice are also envisaged.

公开(公告)号：US20240299381A1

公开(公告)日：2024-09-12

申请号：US18488456

申请日：2023-10-17

Applicant: AbbVie Inc.

Inventor： Sandra L. Goss ,  Cheri E. Klein ,  Juki Wing-Keung Ng ,  Ahmed Salem

IPC: A61K31/505 ,  A61K9/00 ,  A61K31/4178 ,  A61K31/496 ,  A61K31/513 ,  A61K31/565 ,  A61K31/567

CPC classification number: A61K31/505 ,  A61K9/0053 ,  A61K31/4178 ,  A61K31/496 ,  A61K31/513 ,  A61K31/565 ,  A61K31/567

Abstract: The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.

公开(公告)号：US12065296B2

公开(公告)日：2024-08-20

申请号：US17159924

申请日：2021-01-27

Applicant: AMCOR FLEXIBLES NORTH AMERICA, INC.

Inventor： Jennifer Riis ,  Yuan Liu ,  Lyndsey A. McMillan ,  Christopher L. Osborn ,  Rishabh Jain

IPC: B65D65/40 ,  A61K9/70 ,  A61K31/167 ,  A61K31/4468 ,  A61K31/465 ,  A61K31/565 ,  B32B7/12 ,  B32B15/085 ,  B32B27/08 ,  B32B27/10 ,  B32B27/30 ,  B32B27/32 ,  B32B27/34 ,  B32B27/36 ,  B65B9/06 ,  B65D65/14

CPC classification number: B65D65/40 ,  A61K9/7023 ,  A61K9/703 ,  A61K31/167 ,  A61K31/4468 ,  A61K31/465 ,  A61K31/565 ,  B32B7/12 ,  B32B15/085 ,  B32B27/08 ,  B32B27/10 ,  B32B27/308 ,  B32B27/32 ,  B32B27/325 ,  B32B27/34 ,  B32B27/36 ,  B65B9/06 ,  B65D65/14 ,  B32B2255/10 ,  B32B2255/26 ,  B32B2307/31 ,  B32B2307/70 ,  B32B2307/7244 ,  B32B2307/7246 ,  B32B2439/40 ,  B32B2439/80 ,  Y10T428/31797

Abstract: A film for packaging a product that has a pharmaceutical active agent includes a product-contacting sealing layer. The product contacting layer includes at least 90 wt. % of an ethylene norbornene copolymer having a glass transition temperature in a range from 50° C. to 110° C. The pharmaceutical active agent comprises a Hansen Solubility Parameter for the product-contacting sealing layer of 0.5 or greater.

公开(公告)号：US20240252428A1

公开(公告)日：2024-08-01

申请号：US18559268

申请日：2022-05-06

Applicant: THE POPULATION COUNCIL, INC.

Inventor： George William CREASY, II ,  Ruth Beverly MERKATZ ,  Marlena PLAGIANOS ,  Regine SITRUK-WARE ,  Bruce VARIANO

IPC: A61K9/00 ,  A61K31/565 ,  A61K31/573 ,  A61P15/18

CPC classification number: A61K9/0036 ,  A61K31/565 ,  A61K31/573 ,  A61P15/18

Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is suitable for four quarterly product-use cycles or for a 365-day product-use cycle.

公开(公告)号：US20240252348A1

公开(公告)日：2024-08-01

申请号：US18410155

申请日：2024-01-11

Applicant: JUNIPER PHARMACEUTICALS, INC. N/K/A CATALENT JNP, INC.

Inventor： Bridget Martell ,  David Friend ,  Martin Doorbar ,  Shen Luk

IPC: A61F6/08 ,  A61K9/00 ,  A61K31/565 ,  A61K31/57 ,  A61K47/32 ,  A61L31/04 ,  A61L31/16

CPC classification number: A61F6/08 ,  A61K9/0036 ,  A61K31/565 ,  A61K31/57 ,  A61K47/32 ,  A61L31/048 ,  A61L31/16 ,  A61L2300/43

Abstract: Disclosed herein are segmented EVA Rings that contain progesterone that can be used to prevent preterm birth in subjects with a shortened cervix or to treat luteal phase deficiency or as luteal phase support.

公开(公告)号：US20240197635A1

公开(公告)日：2024-06-20

申请号：US18548816

申请日：2022-03-03

Applicant: VeraMorph LLC

Inventor： Paul Douglas Godfrin

IPC: A61K9/14 ,  A61K31/565

CPC classification number: A61K9/146 ,  A61K31/565

Abstract: The present disclosure relates to the composition and methods of manufacturing and use of dissociating polymeric matrix oral dosages (disintegrating pre-formed oral dosage hydrogels) loaded with fulvestrant as an orally delivered therapy for the treatment of diseases, particularly cancer and especially metastatic breast cancer.

公开(公告)号：US20240180909A1

公开(公告)日：2024-06-06

申请号：US18494554

申请日：2023-10-25

Applicant: AbbVie Inc.

Inventor： Mohamad Shebley

IPC: A61K31/513 ,  A61K31/565 ,  A61K31/567 ,  A61P15/00 ,  A61P19/00

CPC classification number: A61K31/513 ,  A61K31/565 ,  A61K31/567 ,  A61P15/00 ,  A61P19/00

Abstract: The present invention relates to dosing regimens for GnRH receptor antagonists, and, in particular, dosing regimens for 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, in subjects suffering from, for example, endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids, to minimize changes in bone mineral density associated with such GnRH receptor antagonists.

公开(公告)号：US20240148608A1

公开(公告)日：2024-05-09

申请号：US18393974

申请日：2023-12-22

Applicant: MEDISCA PHARMACEUTIQUE INC.

Inventor： Panagiota DANOPOULOS

IPC: A61J1/05 ,  A61J3/04 ,  A61K9/00 ,  A61K9/06 ,  A61K9/107 ,  A61K31/045 ,  A61K31/135 ,  A61K31/137 ,  A61K31/192 ,  A61K31/195 ,  A61K31/196 ,  A61K31/197 ,  A61K31/351 ,  A61K31/4418 ,  A61K31/4422 ,  A61K31/445 ,  A61K31/4458 ,  A61K31/565 ,  A61K31/57 ,  A61K31/7048 ,  A61K33/14 ,  A61K47/10 ,  A61K47/26 ,  A61K47/38 ,  A61K47/42 ,  A61K47/46 ,  B01F29/00 ,  B01F29/10 ,  B01F29/32 ,  B01F31/00 ,  B01F35/22 ,  B01F35/42 ,  B65B7/16

CPC classification number: A61J1/05 ,  A61J3/04 ,  A61K9/0034 ,  A61K9/06 ,  A61K9/107 ,  A61K31/045 ,  A61K31/135 ,  A61K31/137 ,  A61K31/192 ,  A61K31/195 ,  A61K31/196 ,  A61K31/197 ,  A61K31/351 ,  A61K31/4418 ,  A61K31/4422 ,  A61K31/445 ,  A61K31/4458 ,  A61K31/565 ,  A61K31/57 ,  A61K31/7048 ,  A61K33/14 ,  A61K47/10 ,  A61K47/26 ,  A61K47/38 ,  A61K47/42 ,  A61K47/46 ,  B01F29/10 ,  B01F29/32 ,  B01F29/40 ,  B01F29/401 ,  B01F29/4011 ,  B01F29/40221 ,  B01F31/00 ,  B01F35/2209 ,  B01F35/421 ,  B65B7/16 ,  B01F29/40365

Abstract: A dispensing container and adapter system for use with a planetary mixer is disclosed. The dispensing container has a longitudinal axis and a transverse axis. The dispensing container may include a nozzle and a removable cap to cover the nozzle. The removable cap may have a first width dimension measured along the transverse axis. The dispensing container may include a body having a second width dimension measured along the transverse axis. An adapter may receive the dispensing container. The adapter may include a cavity to receive the removable cap. The cavity may have a cavity width that exceeds the first width dimension. The adapter may also include a recess for receiving a portion of the dispensing container. The recess may extend from the cavity. At least a portion of the recess may have a width dimension smaller than both the first width dimension and the second width dimension.